I have a piece in the latest issue of the magazine, arguing that the U.S. is an outlier in ‘gender-affirming care’ for minors:

In 2020, a Finnish review concluded that “gender-affirming” treatment was “experimental” and that talk therapy was preferable. Swedish medical authorities concluded that, for minors, the risks of medical transition “currently outweigh the benefits.” The French National Academy of Medicine urged similar caution in 2022, as did the Norwegian Healthcare Investigation Board in 2023. The Europeans cite the new demographic of (disproportionately female) adolescents, the greater visibility of detransitioners (those who experience post-transition regret), and insufficient evidence of the effectiveness of the treatments as reasons to be cautious. But in the United States, as Levine et al. note, “medical organizations so far have chosen to use their eminence to shield the practice of pediatric ‘gender affirmation’ from scrutiny.”